Thyroid hormone-responsive pituitary hyperplasia independent of somatostatin receptor 2

被引:10
作者
Brinkmeier, ML
Stahl, JH
Gordon, DF
Ross, BD
Sarapura, VD
Dowding, JM
Kendall, SK
Lloyd, RV
Ridgway, EC
Camper, SA
机构
[1] Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Radiol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA
[4] Univ Colorado, Hlth Sci Ctr, Div Endocrinol Metab Diabet, Denver, CO 80262 USA
[5] Mayo Clin, Div Anatom Pathol, Rochester, MN 55905 USA
关键词
D O I
10.1210/me.15.12.2129
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mice homozygous for the targeted disruption of the glycoprotein hormone alpha -subunit (alpha Gsu) display hypertrophy and hyperplasia of the anterior pituitary thyrotropes. Thyrotrope hyperplasia results in tumors in aged alpha Gsu(-/-) mice. These adenomatous pituitaries can grow independently as intrascapular transplants in hypothyroid mice, suggesting that they have progressed beyond simple hyperplasia. We used magnetic resonance imaging to follow the growth and regression of thyrotrope adenomatous hyperplasia in response to thyroid hormone treatment and discovered that the tumors retain thyroid hormone responsiveness. Somatostatin (SMST) and its diverse receptors have been implicated in cell proliferation and tumorigenesis. To test the involvement of SMST receptor 2 (SMSTR2) in pituitary tumor progression and thyroid hormone responsiveness in alpha Gsu(-/-) mutants, we generated Smstr2(-/-), alpha Gsu(-/-) mice. Smstr2(-/-), alpha Gsu(-/-) mice develop hyperplasia of thyrotropes, similar to alpha Gsu-/- mutants, demonstrating that SMSTR2 is dispensable for the development of pituitary adenomatous hyperplasia. Thyrotrope hyperplasia in Smstr2(-/-), alpha Gsu(-/-) mice regresses in response to T-4 treatment, suggesting that SMSTR2 is not required in the T-4 feedback loop regulating TSH secretion.
引用
收藏
页码:2129 / 2136
页数:8
相关论文
共 43 条
  • [1] Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states
    Agarwal, SK
    Kester, MB
    Debelenko, LV
    Heppner, C
    EmmertBuck, MR
    Skarulis, MC
    Doppman, JL
    Kim, YS
    Lubensky, IA
    Zhuang, ZP
    Green, JS
    Guru, SC
    Manickam, P
    Olufemi, SE
    Liotta, LA
    Chandrasekharappa, SC
    Collins, FS
    Spiegel, AM
    Burns, AL
    Marx, SJ
    [J]. HUMAN MOLECULAR GENETICS, 1997, 6 (07) : 1169 - 1175
  • [2] AN ALPHA-SUBUNIT-SECRETING CELL-LINE DERIVED FROM A MOUSE THYROTROPE TUMOR
    AKERBLOM, IE
    RIDGWAY, EC
    MELLON, PL
    [J]. MOLECULAR ENDOCRINOLOGY, 1990, 4 (04) : 589 - 596
  • [3] Alarid ET, 1996, DEVELOPMENT, V122, P3319
  • [4] The pathology of pituitary tumors
    Asa, SL
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1999, 28 (01) : 13 - +
  • [5] The cytogenesis and pathogenesis of pituitary adenomas
    Asa, SL
    Ezzat, S
    [J]. ENDOCRINE REVIEWS, 1998, 19 (06) : 798 - 827
  • [6] Cloning, expression, pharmacology and tissue distribution of the mouse somatostatin receptor subtype 5
    Baumeister, H
    Kreuzer, OJ
    Roosterman, D
    Schäfer, J
    Meyerhof, W
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 1998, 10 (04) : 283 - 290
  • [7] Mono- and plurihormonal thyrotropic pituitary adenomas:: pathological, hormonal and clinical studies in 12 patients
    Bertholon-Grégoire, M
    Trouillas, J
    Guigard, MP
    Loras, B
    Tourniaire, J
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (06) : 519 - 527
  • [8] Molecular basis of pituitary dysfunction in mouse and human
    Cushman, LJ
    Camper, SA
    [J]. MAMMALIAN GENOME, 2001, 12 (07) : 485 - 494
  • [9] DAVISSON M, 1995, TRENDS GENET, V11, P35
  • [10] EXPRESSION OF MESSENGER-RNA FOR SOMATOSTATIN RECEPTOR (SSTR) TYPE-2 AND TYPE-5 IN INDIVIDUAL, RAT PITUITARY-CELLS - A DOUBLE-LABELING IN-SITU HYBRIDIZATION ANALYSIS
    DAY, R
    DONG, WJ
    PANETTA, R
    KRAICER, J
    GREENWOOD, MT
    PATEL, YC
    [J]. ENDOCRINOLOGY, 1995, 136 (11) : 5232 - 5235